Mycenax Biotech Inc.


Please enter the company code as 4726 Go to Link

Mycenax on Bio2Business (BOS) in Basel 2018


Mycenax business development team attended Bio2Business(BOS) on the 19th to 20th of June 2018 in Basel.
The purpose of this participation is to introduce advanced technology, exchanging information and searching for cooperation opportunities with various attendee from leading pharmaceutical companies such as Sanofi, Bayer, and others. As a CMC-specialized CDMO, Mycenax provides comprehensive and integrated services to our customers; from process development, formulation development, analytical methods development/ qualification, protein characterization to clinical and commercial scale cGMP manufacturing, and regulatory support. Moreover, self-developed biological drug, TuNEX® and LusiNEX, are promoted to potential partners for sales, marketing, and joint development in this exhibition!
BOS 2018 comprised the existing CMC focused event but in addition, added a new discovery outsourcing component, creating an enlarged 2-day conference in Basel, Switzerland. The new format will allow discovery and development teams the opportunity to come together to share experience and knowledge from discovery to development.